CAR-T cell patients monitored for 15 years in new study
NCT ID NCT03375619
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital & Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can an immune booster outsmart brain lymphoma?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- A shot at safer CAR t: early brain protection for lymphoma patients?